Vile R - Search Results

1

Euro targeting in Leiden: the fourth meeting of the EWGT, University of Leiden, 14-17 November 1996.

Diaz RM, Vile R. Diaz RM, et al. Among authors: vile r. Gene Ther. 1997 Jun;4(6):501-3. doi: 10.1038/sj.gt.3300445. Gene Ther. 1997. PMID: 9231064 No abstract available.

2

Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?

Harrington K, Alvarez-Vallina L, Crittenden M, Gough M, Chong H, Diaz RM, Vassaux G, Lemoine N, Vile R. Harrington K, et al. Among authors: vile r. Hum Gene Ther. 2002 Jul 20;13(11):1263-80. doi: 10.1089/104303402760128504. Hum Gene Ther. 2002. PMID: 12162810 Review.

3

Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer.

Diaz RM, Todryk S, Chong H, Hart IR, Sikora K, Dorudi S, Vile RG. Diaz RM, et al. Among authors: vile rg. Gene Ther. 1998 Jul;5(7):869-79. doi: 10.1038/sj.gt.3300690. Gene Ther. 1998. PMID: 9813657

4

Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.

Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R. Boisgerault N, et al. Among authors: vile r. Mol Ther. 2013 Aug;21(8):1507-16. doi: 10.1038/mt.2013.116. Epub 2013 Jun 11. Mol Ther. 2013. PMID: 23752316 Free PMC article.

5

Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A, Vile R. Ilett E, et al. Among authors: vile r. Mol Ther. 2014 Oct;22(10):1851-63. doi: 10.1038/mt.2014.118. Epub 2014 Jun 24. Mol Ther. 2014. PMID: 24957982 Free PMC article.

6

The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.

Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, Pandha H, Melcher A, Harrington K, Diaz RM, Vile R. Alonso-Camino V, et al. Among authors: vile r. Mol Ther. 2014 Nov;22(11):1936-48. doi: 10.1038/mt.2014.134. Epub 2014 Jul 25. Mol Ther. 2014. PMID: 25059678 Free PMC article.

7

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K, Coffey M, Melcher A, Vile R. Rajani K, et al. Among authors: vile r. Mol Ther. 2016 Feb;24(1):166-74. doi: 10.1038/mt.2015.156. Epub 2015 Aug 27. Mol Ther. 2016. PMID: 26310630 Free PMC article.

8

Novel integrating adenoviral/retroviral hybrid vector for gene therapy.

Murphy SJ, Chong H, Bell S, Diaz RM, Vile RG. Murphy SJ, et al. Hum Gene Ther. 2002 Apr 10;13(6):745-60. doi: 10.1089/104303402317322302. Hum Gene Ther. 2002. PMID: 11936973

9

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.

Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Galanis E, et al. Among authors: vile r. Hum Gene Ther. 2001 May 1;12(7):811-21. doi: 10.1089/104303401750148766. Hum Gene Ther. 2001. PMID: 11339897

10

A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.

Emiliusen L, Gough M, Bateman A, Ahmed A, Voellmy R, Chester J, Diaz RM, Harrington K, Vile R. Emiliusen L, et al. Among authors: vile r. Gene Ther. 2001 Jul;8(13):987-98. doi: 10.1038/sj.gt.3301470. Gene Ther. 2001. PMID: 11438833

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

307 results

Search Page